Clinical Trial Update: Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1b/2 study evaluating the combination of retaspimycin HCl (IPI-504) and everolimus in KRAS-mutant non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Everolimus (everolimus)
• Retaspimycin HCl (IPI-504) (retaspimycin hydrochloride)

Snippet

Sponsor: Infinity Pharmaceuticals, Inc. | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED